The company also encounters competitive risks from other organizations developing therapies for chronic kidney disease.

ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company ...

ProKidney shares soar on promising Rilparencel mid-stage data for chronic kidney disease. But PROK stock remains a high-risk ...

ProKidney’s stock was the biggest gainer and most actively traded on Tuesday following “very intriguing” news regarding the ...

Shares of ProKidney surged more than 500% on Tuesday following upbeat results from its Phase 2 REGEN-007 study and a price ...

ProKidney (NASDAQ: PROK) experienced a surge of 515% during Tuesday's trading session and gained additional 8.58% after-hours ...

At one point, ProKidney had been running an international phase 3 trial, dubbed PROACT 2, of rilparencel alongside the ...

Shares of ProKidney (NASDAQ:PROK) climbed ~56% in the premarket on Tuesday after the cell therapy developer announced ...

ProKidney stock jumps after Phase 2 trial shows rilparencel significantly slowed kidney function decline in patients with ...

A mixed bag of top-line phase II data prompted stellar stock results for Prokidney Corp. and its chronic kidney disease (CKD) ...

ProKidney shares jumped 56% in premarket trading after reporting positive topline results from a select population group in a Phase 2 trial evaluating rilparencel in patients with chronic kidney ...

ProKidney presented results in May from its RMCL-002 multicenter phase 2 trial at the European Renal Association meeting in Stockholm. Patients participating in the trial had an eGFR between 20 ...